77 related articles for article (PubMed ID: 21868340)
1. [Expressions of OCT4 and CD133 and their correlation in colonic cancer].
Chen WS; Ma L; Hu XY; Liu XY; Jin C; Li ZB; Li WD
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1434-6. PubMed ID: 21868340
[TBL] [Abstract][Full Text] [Related]
2. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
4. CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis.
Silinsky J; Grimes C; Driscoll T; Green H; Cordova J; Davis NK; Li L; Margolin DA
J Surg Res; 2013 Nov; 185(1):113-8. PubMed ID: 23777983
[TBL] [Abstract][Full Text] [Related]
5. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
Li XF; Guo XG; Yang YY; Liu AY
Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
[TBL] [Abstract][Full Text] [Related]
6. [Expressions of CD133 and CD44 in gastric adenocarcinoma and their relationship with E-cadherin expression].
Lu G; Wu X; Zhou L; Yu L; Wu S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Nov; 33(11):1632-7. PubMed ID: 24273267
[TBL] [Abstract][Full Text] [Related]
7. CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma.
Mărgaritescu C; Pirici D; Cherciu I; Bărbălan A; Cârtână T; Săftoiu A
J Gastrointestin Liver Dis; 2014 Jun; 23(2):161-70. PubMed ID: 24949608
[TBL] [Abstract][Full Text] [Related]
8. [CD133 promotes the invasion and metastasis of gastric cancer via epithelial-mesenchymal transition].
Cai C; Yu JW; Wu JG; Lu RQ; Ni XC; Wang SL; Jiang BJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jul; 16(7):662-7. PubMed ID: 23888452
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of CD133 and CD82/KAI1 in bladder urothelial carcinoma and their correlation with vasculogenic mimicry].
Yu L; Wu S; Zhou L; Song W; Wang D
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Sep; 33(9):1336-40. PubMed ID: 24067216
[TBL] [Abstract][Full Text] [Related]
10. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells.
Shen WW; Zeng Z; Zhu WX; Fu GH
J Mol Med (Berl); 2013 Aug; 91(8):989-1000. PubMed ID: 23619912
[TBL] [Abstract][Full Text] [Related]
11. [miR-145 inhibits lung adenocarcinoma stem cells proliferation by targeting OCT4 gene].
Zhang S; Wu Y; Feng D; Zhang Z; Jiang F; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):317-22. PubMed ID: 21496429
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis.
Bellizzi A; Sebastian S; Ceglia P; Centonze M; Divella R; Manzillo EF; Azzariti A; Silvestris N; Montemurro S; Caliandro C; De Luca R; Cicero G; Rizzo S; Russo A; Quaranta M; Simone G; Paradiso A
J Cell Physiol; 2013 Feb; 228(2):408-15. PubMed ID: 22740326
[TBL] [Abstract][Full Text] [Related]
13. Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma.
Kim K; Ro JY; Kim S; Cho YM
Hum Pathol; 2012 Dec; 43(12):2109-16. PubMed ID: 22944295
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary.
Trinh DT; Shibata K; Hirosawa T; Umezu T; Mizuno M; Kajiyama H; Kikkawa F
J Obstet Gynaecol Res; 2012 May; 38(5):841-8. PubMed ID: 22448662
[TBL] [Abstract][Full Text] [Related]
15. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
16. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of changes in the expression of stem cell markers in the peripheral blood of patients with colon cancer.
Padín-Iruegas ME; Herranz-Carnero M; Aguin-Losada S; Brozos-Vazquez E; Anido-Herranz U; Antunez-Lopez JR; Ruibal-Morell A; López-López R
Oncol Rep; 2013 Jun; 29(6):2467-72. PubMed ID: 23545848
[TBL] [Abstract][Full Text] [Related]
18. CD133 marks for colorectal adenocarcinoma.
Chew MF; Teoh KH; Cheah PL
Malays J Pathol; 2012 Jun; 34(1):25-8. PubMed ID: 22870594
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
